As with prostate cancer, AURKA has been linked to the disease but its inhibition does not alter MYCN levels, suggesting a difference in activity in MYCN-amplified non-small lung cancer cells (NSCLC) compared to MYCN-amplified neuroblastoma and prostate cancer [184]. The gene discussed is MYCN; the disease is prostate cancer.